Description: Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Home Page: www.oxurion.com
Gaston Geenslaan 1
Leuven,
3001
Belgium
Phone:
32 1 675 13 10
Officers
| Name | Title |
|---|---|
| Mr. Thomas Graney C.F.A. | CEO, CFO & Director |
| Mr. Wouter Piepers | Global Head of Corp. Communications & Investor Relations |
| Ms. Kathleen Paisley | Chief Legal Officer & Compliance Officer |
| Ms. Julie Binon | Chief People Officer |
| Dr. Andy De Deene M.B.A., M.D. | Chief Devel. Officer |
| Mr. Michael Dillen | Chief Bus. Officer & Company Sec. |
Exchange: BR
Country: BE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.2488 |
| Price-to-Sales TTM: | 4.0655 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 42 |